Education
About Us
Working with TipRanks
Follow Us
Renalytix (RNLXY)
OTHER OTC:RNLXY
RNLXY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.12 - $0.50
Previous CloseN/A
Volume36.17K
Average Volume (3M)56.30K
Market Cap
$30.04M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)8.25M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Nov 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding165,603,010
10 Day Avg. Volume47,131
30 Day Avg. Volume56,297
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renalytix News
PremiumCompany Announcements
Renalytix AI Plc ADR Earnings Call: FDA Approval and Growth Prospects
PremiumCompany Announcements
Renalytix AI Plc ADR Reports Strong Growth and Strategic ProgressOptions Prices
Currently, No data available
---
Ownership Overview
21.14% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
78.85% Public Companies and
Individual Investors
RNLXY FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was $0.12 and its highest was $0.50 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $30.04M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 04, 2025 which is in 108 days.
How were Renalytix’s earnings last quarter?
Currently, no data Available
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 165,603,010 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renalytix?
Among the largest hedge funds holding Renalytix’s share is Gilder Gagnon Howe & Co LLC.. It holds Renalytix’s shares valued at 0.
Company Description
Renalytix
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
RNLXY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights significant achievements such as FDA approval, Medicare reimbursement, and strong revenue growth forecasts. However, challenges remain in scaling operations and international expansion.Read More>Technical Analysis
Rockwell Med
―
Rein Therapeutics
―
Lantern Pharma
―
Generation Bio
―
Connect Biopharma Holdings
―